论文部分内容阅读
对20例卵巢癌合并恶性腹水的患者提取股水中的肿瘤浸润淋巴细胞（TIL），在体外经重组白细胞介素2（rIL－2）诱导、扩增后回输病人腹腔。培养前后测定淋巴细胞亚群CD3、CD4、CDS、IL－2受体及细胞毒活性，并对TIL／rIL－2治疗前后的腹水病理细胞、CEA及CA125的变化进行监测。结果表明：腹水TIL经培养扩增后，CD8、IL－2受体及细胞毒活性明显增加（P＜0．01），腹水CEA及CA125水平均有不同程度下降．部分患者腹水病理细胞消失。经本法治疗腹水消失者占60％，总有效率80％，随访1～6月未见明显毒、副作用。
Tumor infiltrating lymphocytes (TILs) were extracted from 20 patients with malignant ascites and were induced by recombinant interleukin-2 (rIL-2) in vitro and then were transfused into the peritoneal cavity of patients. The levels of CD3, CD4, CDS, IL-2 and cytotoxic activity of lymphocyte subsets were measured before and after culture. The changes of pathological cells, CEA and CA125 before and after TIL / rIL-2 treatment were also monitored. The results showed that ascites TIL after culture expansion, CD8, IL-2 receptor and cytotoxic activity was significantly increased (P <0.01), ascites CEA and CA125 levels decreased to varying degrees. Some patients ascites pathological cells disappear. The treatment of ascites disappeared accounted for 60% of the total effective rate of 80%, no significant toxicity and side effects were observed from 1 to 6 months follow-up.